Pharmacological effects of two anti-methamphetamine monoclonal antibodies: Supporting data for lead candidate selection for clinical development

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 9, 2014, Pages 2638-2647

  Laurenzana, Elizabeth M ^a   Stevens, Misty W ^b   Frank, John C ^c   Hambuchen, Michael D ^a   Hendrickson, Howard P ^a   White, Sarah J ^a   Williams, D Keith ^c   Owens, S Michael ^a,b   Gentry, W Brooks ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b InterveXion Therapeutics LLC   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Addiction; Lead candidate selection; Locomotor activity; Methamphetamine; Monoclonal antibody; Overdose; Pharmacokinetics; Rat

Indexed keywords

AMPHETAMINE; METHAMPHETAMINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B4G9; MONOCLONAL ANTIBODY B7F9; UNCLASSIFIED DRUG; PLACEBO;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN BINDING; ARTICLE; BINDING SITE; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; IN VIVO STUDY; LOCOMOTION; MALE; NONHUMAN; RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG EFFECTS; DRUG OVERDOSE; SPRAGUE DAWLEY RAT; TIME FACTOR; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE MODELS, ANIMAL; DRUG OVERDOSE; LOCOMOTION; MALE; METHAMPHETAMINE; PLACEBOS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; TREATMENT OUTCOME;

EID: 84920145004     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.29707     Document Type: Article

References (26)

1. Byrnes-Blake KA, Laurenzana EM, Carroll FI, Abraham P, Gentry WB, Landes RD, Owens SM. Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats. Eur J Pharmacol 2003; 461:119-28; PMID:12586207; http://dx.doi.org/10.1016/S0014-2999(03)01313-X
2. Byrnes-Blake KA, Laurenzana EM, Landes RD, Gentry WB, Owens SM. Monoclonal IgG affinity and treatment time alters antagonism of (+)-methamphetamine effects in rats. Eur J Pharmacol 2005; 521:86-94; PMID:16182279; http://dx.doi.org/10.1016/j.ejphar.2005.08.016
3. Gentry WB, Laurenzana EM, Williams DK, West JR, Berg RJ, Terlea T, Owens SM. Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats. Int Immunopharmacol 2006; 6:968-77; PMID:16644483; http://dx.doi.org/10.1016/j.intimp.2006.01.008
4. McMillan DE, Hardwick WC, Li M, Owens SM. Pharmacokinetic antagonism of (+)-methamphetamine discrimination by a low-affinity monoclonal anti-methamphetamine antibody. Behav Pharmacol 2002; 13:465-73; PMID:12394422; http://dx.doi.org/10.1097/00008877-200209000-00019
5. McMillan DE, Hardwick WC, Li M, Gunnell MG, Carroll FI, Abraham P, Owens SM. Effects of murine-derived anti-methamphetamine monoclonal antibodies on (+)-methamphetamine self-administration in the rat. J Pharmacol Exp Ther 2004; 309:1248-55; PMID:14993256; http://dx.doi.org/10.1124/jpet.103.061762
6. Laurenzana EM, Hendrickson HP, Carpenter D, Peterson EC, Gentry WB, West M, Che Y, Carroll FI, Owens SM. Functional and biological determinants affecting the duration of action and efficacy of anti-(+)-methamphetamine monoclonal antibodies in rats. Vaccine 2009; 27:7011-20; PMID:19800446; http://dx.doi.org/10.1016/j.vaccine.2009.09.072
7. Pentel PR, Dufek MB, Roiko SA, Lesage MG, Keyler DE. Differential effects of passive immunization with nicotine-specific antibodies on the acute and chronic distribution of nicotine to brain in rats. J Pharmacol Exp Ther 2006; 317:660-6; PMID:16407464; http://dx.doi.org/10.1124/jpet.105.097873
8. Gentry WB, Rüedi-Bettschen D, Owens SM. Anti-(+)-methamphetamine monoclonal antibody antagonists designed to prevent the progression of human diseases of addiction. Clin Pharmacol Ther 2010; 88:390-3; PMID:20668443; http://dx.doi.org/10.1038/clpt.2010.155
9. Owens SM, Atchley WT, Hambuchen MD, Peterson EC, Gentry WB. Monoclonal antibodies as pharmacokinetic antagonists for the treatment of (+)-methamphetamine addiction. CNS Neurol Disord Drug Targets 2011; 10:892-8; PMID:22229314; http://dx.doi.org/10.2174/187152711799219370
10. Peterson EC, Gunnell M, Che Y, Goforth RL, Carroll FI, Henry R, Liu H, Owens SM. Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse. J Pharmacol Exp Ther 2007; 322:30-9; PMID:17452421; http://dx.doi.org/10.1124/jpet.106.117150
11. Carroll FI, Abraham P, Gong PK, Pidaparthi RR, Blough BE, Che Y, Hampton A, Gunnell M, Lay JO Jr., Peterson EC, et al. The synthesis of haptens and their use for the development of monoclonal antibodies for treating methamphetamine abuse. J Med Chem 2009; 52:7301-9; PMID:19877685; http://dx.doi.org/10.1021/jm901134w
12. Stevens MW, Tawney RL, West CM, Kight AD, Henry RL, Owens SM, Gentry WB. Preclinical characterization of an anti-methamphetamine monoclonal antibody for human use. MAbs 2014; 6:547-55; PMID:24492290; http://dx.doi.org/10.4161/mabs.27620
13. Rivière GJ, Byrnes KA, Gentry WB, Owens SM. Spontaneous locomotor activity and pharmacokinetics of intravenous methamphetamine and its metabolite amphetamine in the rat. J Pharmacol Exp Ther 1999; 291:1220-6; PMID:10565845
14. Milesi-Hallé A, Hendrickson HP, Laurenzana EM, Gentry WB, Owens SM. Sex- and dose-dependency in the pharmacokinetics and pharmacodynamics of (+)-methamphetamine and its metabolite (+)-amphetamine in rats. Toxicol Appl Pharmacol 2005; 209:203-13; PMID:15916788; http://dx.doi.org/10.1016/j.taap.2005.04.007
15. Cook CE, Jeffcoat AR, Hill JM, Pugh DE, Patetta PK, Sadler BM, White WR, Perez-Reyes M. Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. Drug Metab Dispos 1993; 21:717-23; PMID:8104133
16. Rivière GJ, Gentry WB, Owens SM. Disposition of methamphetamine and its metabolite amphetamine in brain and other tissues in rats after intravenous administration. J Pharmacol Exp Ther 2000; 292:1042-7; PMID:10688621
17. Laurenzana EM, Gunnell MG, Gentry WB, Owens SM. Treatment of adverse effects of excessive phencyclidine exposure in rats with a minimal dose of monoclonal antibody. J Pharmacol Exp Ther 2003; 306:1092-8; PMID:12829731; http://dx.doi.org/10.1124/jpet.103.053140
18. Pitas G, Laurenzana EM, Williams DK, Owens SM, Gentry WB. Anti-phencyclidine monoclonal antibody binding capacity is not the only determinant of effectiveness, disproving the concept that antibody capacity is easily surmounted. Drug Metab Dispos 2006; 34:906-12; PMID:16507651
19. Carrera MRA, Ashley JA, Hoffman TZ, Isomura S, Wirsching P, Koob GF, Janda KD. Investigations using immunization to attenuate the psychoactive effects of nicotine. Bioorg Med Chem 2004; 12:563-70; PMID:14738965; http://dx.doi.org/10.1016/j.bmc.2003.11.029
20. Grillo-López AJ, White CA, Dallaire BK, Varns CL, Shen CD, Wei A, Leonard JE, McClure A, Weaver R, Cairelli S, et al. Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Curr Pharm Biotechnol 2000; 1:1-9; PMID:11467356; http://dx.doi.org/10.2174/1389201003379059
21. Migone T-S, Subramanian GM, Zhong J, Healey LM, Corey A, Devalaraja M, Lo L, Ullrich S, Zimmerman J, Chen A, et al. Raxibacumab for the treatment of inhalational anthrax. N Engl J Med 2009; 361:135-44; PMID:19587338; http://dx.doi.org/10.1056/NEJMoa0810603
22. Cruickshank CC, Dyer KR. A review of the clinical pharmacology of methamphetamine. Addiction 2009; 104:1085-99; PMID:19426289; http://dx.doi.org/10.1111/j.1360-0443.2009.02564.x
23. Hardin JSJ, Wessinger WDW, Wenger GRG, Proksch JWJ, Laurenzana EME, Owens SMS. A single dose of monoclonal anti-phencyclidine IgG offers long-term reductions in phencyclidine behavioral effects in rats. J Pharmacol Exp Ther 2002; 302:119-26; PMID:12065708; http://dx.doi.org/10.1124/jpet.302.1.119
24. Robinson TE, Becker JB. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res 1986; 396:157-98; PMID:3527341; http://dx.doi.org/10.1016/0165-0173(86)90002-0
25. Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. Baltimore: Williams & Wilkins; 1995.
26. Lam FC, Hung CT, Perrier DG. Estimation of variance for harmonic mean half-lives. J Pharm Sci 1985; 74:229-31; PMID:3989700; http://dx.doi.org/10.1002/jps.2600740229